Molnupiravir is an antiviral medication that gained attention during the COVID-19 pandemic. It was developed by Merck & Co. in collaboration with Ridgeback Biotherapeutics. Molnupiravir is an oral medication designed to inhibit the replication of RNA viruses, including coronaviruses like SARS-CoV-2.
The mechanism of action of Molnupiravir involves introducing errors into the viral genetic material during replication, leading to the production of nonfunctional viral particles. This disruption in the replication process can reduce the viral load in infected individuals and potentially limit the severity of the disease.
Molnupiravir garnered interest due to its potential to treat COVID-19 patients, especially those at high risk of severe illness or hospitalization. Clinical trials have been conducted to evaluate its efficacy and safety, with some studies showing promising results in reducing viral shedding and improving clinical outcomes in certain patient groups.
| CAS | 2349386-89-4 |
| Country Of Origin | China |
| Manufacturer | LongilatBio |
| Molecular Formula | C13H19N3O7 |
| Indication | Treatment Of COVID-19 |
| Generic Name | EIDD-2801 |
| Shipping Method | Air(UPS, FedEx, TNT, EMS) Or Sea |
| Purity | 99% |
| COA | Available |
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
